Ad
related to: sickle cell nhm portal patient- What Is LYFGENIA?
Learn About LYFGENIA As
A Treatment Option.
- Steps To Treatment
See A Breakdown Of
Treatment With LYFGENIA.
- Find A QTC
Start Your Search For A Qualified
Treatment Center Nearest You.
- FAQs
Your LYFGENIA Questions. Answered.
Review Patient Information.
- What Is LYFGENIA?
Search results
Results From The WOW.Com Content Network
Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders typically inherited. [2] The most common type is known as sickle cell anemia. [2] It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. [2] This leads to a rigid, sickle -like shape under ...
Sickle cell disease. Sickle cell nephropathy is a type of kidney disease associated with sickle cell disease which causes kidney complications as a result of sickling of red blood cells in the small blood vessels. The hypertonic and relatively hypoxic environment of the renal medulla, coupled with the slow blood flow in the vasa recta, favors ...
Acute chest syndrome. The acute chest syndrome is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people with sickle cell anemia. This condition commonly manifests with a new opacification of the lung (s) on a chest x-ray. [1]
A study published in 2013 found that patients seeking care from 2003 through 2008 at an ER for their sickle cell crises experienced 50% longer wait times than patients who arrived at ERs with ...
In patients with sickle cell disease, red blood cells, which are usually disk-shaped, take on a crescent or sickle shape. This change can cause cells to clump together, leading to clots and ...
Treatment is the same as for patients with sickle cell disease. Patients may receive hydroxyurea to induce the protective effects of increased fetal hemoglobin production. They may also benefit from blood transfusions especially during vaso-occlusive crises. Patients may be offered chemoprophylaxis with penicillin.
Victoria Gray. Victoria Gray was the first patient ever to be treated with the gene-editing tool CRISPR for sickle-cell disease. [1] This marked the initial indication that a cure is attainable for individuals born with sickle-cell disease and another severe blood disorder, beta-thalassemia. [1]
Voxelotor. Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. [1][3][4][5][6] Voxelotor is the first hemoglobin oxygen-affinity modulator. [7] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell ...
Ad
related to: sickle cell nhm portal patient